BridgeBio Pharma, Inc

Traded on the St. Petersburg Stock Exchange
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
BridgeBio Pharma, Inc stock price chart
+68%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

BridgeBio Pharma, Inc balance sheet

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

BridgeBio Pharma, Inc cash flows

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

BridgeBio Pharma, Inc multipliers

Report period2018 2019 2020 2021 2022 2023
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

BridgeBio Pharma, Inc profitability

Report period2018 2019 2020 2021 2022 2023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
BridgeBio Pharma, Inc assets
BridgeBio Pharma, Inc cash flows

BridgeBio Pharma, Inc dividend policy

The company doesn't provide dividends

BridgeBio Pharma, Inc shares

TickerNameTypeNominal valueISINPrice
BBIO:USBridgeBio Pharma, Inc.Common share-US10806X1028$29.58
BridgeBio Pharma, Inc news
05.05.2022
BridgeBio Pharma's GAAP loss for 3 months of 2022 was $201.33 million, up 17.7% from $171.082 million in the previous year. Revenue increased 3.7 times to $1.694 billion from $0.462 billion a year earlier.
General information
Company nameBridgeBio Pharma, Inc
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address421 Kipling Street Palo Alto, CA 94301 United States
Mailing address421 Kipling Street Palo Alto, CA 94301 United States
Websiteinvestor.bridgebio.com